Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs to Be Presented at ENDO 2024

Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...

Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Presented at ECE 2024

Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...

Endocrine Society, ESE Publish Joint Guideline on Glucocorticoid-Induced Adrenal Insufficiency 

To kick off a new guideline-writing partnership between the Endocrine Society and the European Society of Endocrinology (ESE), a new guideline on glucocorticoid-induced adrenal insufficiency has just been released. The joint guideline, which was published in the Societies’ respective journals, is designed to help clinicians manage patients who have, or are at risk of developing,...

Staying Curious: How Felix Beuschlein, MD, Has Advanced Adrenal Tumor Care Through Transatlantic Collaboration 

Beuschlein staircase Honored by both the Endocrine Society and the European Society of Endocrinology with the 2024 Transatlantic Alliance Award, Felix Beuschlein, MD, has made significant contributions to endocrine research on both sides of the Atlantic, from Michigan to Switzerland! Endocrine News speaks with Beuschlein about what this award means to him, conducting pioneering research on two...

Primary Aldosteronism Foundation Announces Creation of Alliance to Drive Diagnosis and Treatment of Common Cause of Hypertension

The Primary Aldosteronism Foundation announced the creation of a multi-stakeholder alliance to drive diagnosis and treatment of primary aldosteronism, a common cause of hypertension. The initiative will facilitate the design and implementation of interventions to advance standards of care for primary aldosteronism, a highly prevalent adrenal disease and common cause of hypertension. Primary aldosteronism is...

New Cushing’s Syndrome Research Presented at ENDO 2022

The pharmacology data focus on the human body’s homeostatic response to potent HSD-1 inhibition by SPI-62. Results highlight that urinary free cortisol is distinct from intracellular cortisol that causes symptoms in patients with Cushing’s syndrome or autonomous cortisol secretion. Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology...

All About Adrenal: Analyzing Two Years of Research

ENDO_2022_4C When the ENDO 2022 session “Clinical Year in Review: All Things Adrenal” gets underway, Gary Hammer, MD, PhD, will treat attendees to the series of advances that have been made in adrenal science and clinical practice over the last two years, from adrenal homeostasis, glucocorticoid biology, and adrenal insufficiency to Cushing’s, tumors, pheochromocytoma, and more....

Cortisol Excess: Unsafe at Any Level?

A new study finds that even low levels of the “mild cortisol excess” associated with adrenal incidentalomas can increase cardiometabolic risk.   Benign tumors on adrenal glands may not be so benign when it comes to patients’ overall health, according to the largest study to date on the topic. An international consortium of researchers found...

Adrenal Disorders And Adrenal Cancer Information

Though rare, affecting around 200 people per year, adrenal cancer is no less devastating when a family faces a diagnosis. Because it’s so rare, getting access to the right information and treatment is challenging. It’s not uncommon for a patient with this diagnosis to find that his or her doctor has never faced adrenal cancer before. For that reason, a trusted resource for accurate and timely information is critical to the modern endocrinology practice.

In addition, benign adrenal tumors, which affect one out of every 10 people who have an imaging test done of the adrenal gland, can have serious health effects. To help doctors and patients understand adrenal diseases, including tumors and cancers, Endocrine News has collected a number of recent and relevant articles on the topic on this page. For the information you need about adrenal disease, bookmark this page and refer to it on a regular basis.

Clinical Trials and Recent Research Studies

For doctors to make informed decisions for their patients about adrenal disorders, they need accurate information about the most recent research studies and clinical trials. Sometimes, accessing that information is not easy, especially for rare disorders and diseases. Endocrine News brings all of that research into one place, providing the data you need to make the right decisions for your practice and your patients.

 Providing Hope for Adrenal Cancer Patients

For patients who have been diagnosed with adrenal cancer, this page will provide a measure of hope by offering insight into adrenal cancer treatments. Since only about 200 patients are diagnosed with this particular disease each year, endocrinologists are often unprepared to treat it. Here, however, doctors and patients can find information about what treatment options are available. Research about new, promising treatments will also be posted here as it comes available, providing hope to patients and doctors alike.